Inceptionr LLC Takes Position in Zimmer Biomet Holdings, Inc. $ZBH

Inceptionr LLC bought a new position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 12,359 shares of the medical equipment provider’s stock, valued at approximately $1,217,000.

Several other institutional investors also recently bought and sold shares of the stock. Brighton Jones LLC acquired a new stake in shares of Zimmer Biomet during the 4th quarter worth approximately $204,000. Sivia Capital Partners LLC acquired a new position in shares of Zimmer Biomet in the 2nd quarter valued at $232,000. United Bank boosted its holdings in Zimmer Biomet by 10.7% during the second quarter. United Bank now owns 11,896 shares of the medical equipment provider’s stock worth $1,085,000 after buying an additional 1,153 shares in the last quarter. Atlantic Union Bankshares Corp purchased a new stake in Zimmer Biomet during the second quarter worth $80,000. Finally, Resona Asset Management Co. Ltd. grew its position in Zimmer Biomet by 5.7% during the second quarter. Resona Asset Management Co. Ltd. now owns 67,915 shares of the medical equipment provider’s stock valued at $6,197,000 after buying an additional 3,634 shares during the period. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Zimmer Biomet Stock Performance

ZBH opened at $94.08 on Monday. The firm’s fifty day simple moving average is $92.13 and its two-hundred day simple moving average is $95.60. Zimmer Biomet Holdings, Inc. has a 52-week low of $84.59 and a 52-week high of $114.44. The company has a market cap of $18.41 billion, a price-to-earnings ratio of 26.58, a PEG ratio of 1.92 and a beta of 0.58. The company has a quick ratio of 1.10, a current ratio of 1.98 and a debt-to-equity ratio of 0.55.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 EPS for the quarter, topping analysts’ consensus estimates of $2.38 by $0.04. The business had revenue of $2.24 billion during the quarter, compared to analysts’ expectations of $2.22 billion. Zimmer Biomet had a net margin of 8.56% and a return on equity of 12.93%. The company’s quarterly revenue was up 10.9% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.31 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. Equities analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st will be issued a dividend of $0.24 per share. The ex-dividend date of this dividend is Tuesday, March 31st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.0%. Zimmer Biomet’s dividend payout ratio is presently 27.12%.

Wall Street Analyst Weigh In

A number of research firms have weighed in on ZBH. Sanford C. Bernstein upped their price objective on shares of Zimmer Biomet from $97.00 to $99.00 and gave the stock a “market perform” rating in a research report on Friday, January 9th. Canaccord Genuity Group dropped their target price on Zimmer Biomet from $101.00 to $93.00 and set a “hold” rating on the stock in a research report on Monday, November 10th. Wells Fargo & Company lifted their price target on Zimmer Biomet from $93.00 to $98.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 11th. Evercore raised Zimmer Biomet from an “in-line” rating to an “outperform” rating and upped their price target for the stock from $94.00 to $120.00 in a report on Monday, January 5th. Finally, UBS Group reiterated a “sell” rating and set a $89.00 price target on shares of Zimmer Biomet in a research report on Wednesday, February 11th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, ten have given a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $106.20.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.